U.S. Markets closed

Seattle Genetics, Inc. (SGEN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
51.39-5.16 (-9.12%)
At close: 4:00PM EDT

51.50 0.11 (0.21%)
After hours: 7:53PM EDT

People also watch
IMGNBMRNINCYALNYCLDX
  • Echelon results are out. No 90% or greather but 82% without lung issue (long term terrible from personal knowledge) is still very good. Market reaction is same as when Adcetris received initial FDA approval. CC is either 8:30 this AM (Forbes) or 5:30 this PM (AP)
    Talking about snatching defeat from the jaws of victory.
    Kool
  • Whomever is buying now is going to make a lot of dough in a couple of days.
    Kool
  • New adcetris data in GVHD. "BV is tolerable and has activity in steroid-refractory acute GVHD and merits further
    investigation. " Big market.

    http://www.bloodjournal.org/content/early/2017/05/04/blood-2017-03-772210

  • Hey Satnam, bio sector is ticking up along with SGEN. Better cover your short and cut your losses before you lose your house.
  • Timber..what the heck is causing this tumble?
  • We hv heard from Red yet.
    Are you still here?
    Kool
  • I bought a fresh batch of sgen at around 55. 💵🤑💵
  • *Seattle Genetics Inc /Wa CMO & EVP, R & D Drachman Jonathan G Sold 10,000 Shares With Price Range $64.00 ~ $64.58 on 06/22/2017 - [SGEN]

    Mon Jun 26 20:19:00 2017 EDT

    SID(RTT706262019000440)

    SGEN

    INSIDER_TRADING
  • They usually have something in their sleeve stop the short's raids but this time is crickets.
    BB appear to not buying opportunistically as in the past or else the sty would have been cut kind of short. Hopefully they have a good reason for it.
  • Posted in $ATNM conversation
    Very good news for $ATNM - drug candidate from $SGEN failed. This was competing drug for AML - Iomab-A. Their drug used same antibody CD-33. But they used a toxin to destroy cancer cell. $ATNM used radioactive particle, which has very little toxic affect on patients.

    $ATNM now has a clear field in the AML arena.
  • No getting around it - the failure of Cascade and the suspension of CD-33A investigations represent serious setbacks, though of course the rest of the SGEN pipeline remains robust and promising. It would be helpful if SGEN had conducted a conference call today to offer additional context and to soothe the market, but management remains tone deaf when it comes to public relations and crisis management. Consequently, the waters will be more choppy this week than they need be.
  • Maybe the CD33 trial cancellation is no so bad. CD33 is expressed on both cancerous and normal myeloid cells. The normal CD33 cells play an important part in the immune system so killing them off along with the cancerous cells doesn't produce the best outcome. On the other hand, SGEN has another candidate SGN-CD123A and they claim the CD123 is only expressed on malignant myeloid cells. In other words CD123 is a much better target then CD33.
  • LOAD UP SOME OF IGXT MAJOR BREAKOUT IMMINENT ...
    IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • Selloff to continue till it reach single digit. Funds seems like dumped today
  • Tripped 10% breakers at open.
    What would it have done if the trial failed? Do we have a great management team or what?
    Could not get up early to have a CC to prevent this savagery from happening.
  • Its margin selling!
  • Don't forget to Sell tonight
  • $5 in next 2 days, sell Short
  • I wonder if the village idiot will get tired of talking to himself
  • It will Open $5 tomorrow after news